Zedsen

Executive Summary

Zedsen is a UK-based medical diagnostics company developing a non-invasive, portable, and affordable device for early breast cancer detection using electrical signal processing. Founded in 2019 and headquartered in London, the company aims to increase global access to breast cancer diagnostics, particularly across diverse tissue types. Zedsen's technology leverages electrical impedance spectroscopy to differentiate malignant from benign tissue without radiation or compression, potentially reducing the need for biopsies and enabling screening in low-resource settings. While the company is still in early stages with no disclosed funding rounds or FDA approvals, its approach addresses a critical unmet need in women's health. Zedsen's platform could disrupt traditional mammography and ultrasound-based diagnostics if clinical validation succeeds. The company's progress depends on securing regulatory clearance and clinical evidence to support adoption.

Upcoming Catalysts (preview)

• Q1 2027First-in-human clinical trial results60% success
• Q2 2026Series A funding round50% success
• Q4 2026CE marking or FDA breakthrough device designation40% success